211 related articles for article (PubMed ID: 21596805)
21. Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study.
Hattingen E; Jurcoane A; Bähr O; Rieger J; Magerkurth J; Anti S; Steinbach JP; Pilatus U
Neuro Oncol; 2011 Dec; 13(12):1349-63. PubMed ID: 21890539
[TBL] [Abstract][Full Text] [Related]
22. Outcome of discontinuing bevacizumab prior to malignant glioma progression.
Sherman WJ; Raizer JJ; Grimm SA
J Neurooncol; 2013 Jan; 111(1):87-9. PubMed ID: 23065093
[No Abstract] [Full Text] [Related]
23. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
[TBL] [Abstract][Full Text] [Related]
24. Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab.
Ellingson BM; Cloughesy TF; Lai A; Nghiemphu PL; Pope WB
Magn Reson Med; 2012 Jan; 67(1):237-45. PubMed ID: 21702063
[TBL] [Abstract][Full Text] [Related]
25. Rapid Early Tumor Progression is Prognostic in Glioblastoma Patients.
Palmer JD; Bhamidipati D; Shukla G; Sharma D; Glass J; Kim L; Evans JJ; Judy K; Farrell C; Andrews DW; Wang ZW; Peiper SC; Werner-Wasik M; Shi W
Am J Clin Oncol; 2019 May; 42(5):481-486. PubMed ID: 30973372
[TBL] [Abstract][Full Text] [Related]
26. Disseminated progression of glioblastoma after treatment with bevacizumab.
Bloch O; Safaee M; Sun MZ; Butowski NA; McDermott MW; Berger MS; Aghi MK; Parsa AT
Clin Neurol Neurosurg; 2013 Sep; 115(9):1795-801. PubMed ID: 23706614
[TBL] [Abstract][Full Text] [Related]
27. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
[TBL] [Abstract][Full Text] [Related]
28. Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study.
Park KJ; Kano H; Iyer A; Liu X; Niranjan A; Flickinger JC; Lieberman FS; Lunsford LD; Kondziolka D
J Neurooncol; 2012 Apr; 107(2):323-33. PubMed ID: 22057917
[TBL] [Abstract][Full Text] [Related]
29. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
Pichler J; Pachinger C; Pelz M; Kleiser R
Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
[TBL] [Abstract][Full Text] [Related]
30. Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker.
Jain R; Scarpace LM; Ellika S; Torcuator R; Schultz LR; Hearshen D; Mikkelsen T
J Neurooncol; 2010 Feb; 96(3):423-31. PubMed ID: 19859666
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients.
Rieger J; Bähr O; Müller K; Franz K; Steinbach J; Hattingen E
J Neurooncol; 2010 Aug; 99(1):49-56. PubMed ID: 20035366
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
[TBL] [Abstract][Full Text] [Related]
33. Enhancing tumor apparent diffusion coefficient histogram skewness stratifies the postoperative survival in recurrent glioblastoma multiforme patients undergoing salvage surgery.
Zolal A; Juratli TA; Linn J; Podlesek D; Sitoci Ficici KH; Kitzler HH; Schackert G; Sobottka SB; Rieger B; Krex D
J Neurooncol; 2016 May; 127(3):551-7. PubMed ID: 26830088
[TBL] [Abstract][Full Text] [Related]
34. Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumab.
Takano S; Kimu H; Tsuda K; Osuka S; Nakai K; Yamamoto T; Ishikawa E; Akutsu H; Matsuda M; Matsumura A
Acta Neurochir Suppl; 2013; 118():185-9. PubMed ID: 23564129
[TBL] [Abstract][Full Text] [Related]
35. Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Kebir S; Schaub C; Junold N; Hattingen E; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Galldiks N; Weller J; Mack F; Tzaridis T; Bähr O; Seidel C; Schlegel U; Schmidt-Graf F; Rohde V; Borchers C; Tabatabai G; Hänel M; Sabel M; Gerlach R; Krex D; Belka C; Vatter H; Proescholdt M; Glas M; Herrlinger U
J Neurooncol; 2019 Sep; 144(3):501-509. PubMed ID: 31325144
[TBL] [Abstract][Full Text] [Related]
36. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
[TBL] [Abstract][Full Text] [Related]
37. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
[TBL] [Abstract][Full Text] [Related]
38. Clinical Impact of Bevacizumab in Patients with Relapsed Glioblastoma: Focus on a Real-Life Monocentric SurVey (SV1 Study).
Rivoirard R; Chargari C; Guy JB; Nuti C; Peoc'h M; Forest F; Falk AT; Garin C; Adjabi A; Hoarau D; Fotso MJ; Langrand Escure J; Moriceau G; Fournel P; Boutet C; Magné N
Chemotherapy; 2016; 61(5):269-74. PubMed ID: 27057742
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme.
Elson A; Paulson E; Bovi J; Siker M; Schultz C; Laviolette PS
J Neurooncol; 2015 May; 123(1):179-88. PubMed ID: 25894597
[TBL] [Abstract][Full Text] [Related]
40. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab.
Ellingson BM; Cloughesy TF; Lai A; Nghiemphu PL; Lalezari S; Zaw T; Motevalibashinaeini K; Mischel PS; Pope WB
J Neurooncol; 2012 Jan; 106(1):111-9. PubMed ID: 21706273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
